Dominique Lamarque

Dr. Dominique Lamarque

Department of Gastroenterology, Ambroise Paré Hospital, 92104 Boulogne-Billancourt, France
orcid

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 November 2022 in Journal of the European Optical Society-Rapid Publications
Verified
Journal Article
Open access
PDF file
MKMyeongseop Kim
Myeongseop Kim
HLHee Ryung Lee
Hee Ryung Lee
RORazvigor Ossikovski
Razvigor Ossikovski
AMAude Malfait-Jobart
Aude Malfait-Jobart
DLDominique Lamarque
Dominique Lamarque
Tatiana NovikovaTatiana Novikova
Tatiana Novikova
We investigate a possibility of producing the quantitative optical metrics to characterize the evolution of gastric tissue from healthy conditions via inflammation to cancer by using Mueller microscopy of gastric biopsies, regression model and statistical analysis of the predicted images. For this purpose the unstained sections of human gastric tissue biopsies at different pathological conditions were measured with the custom-built Mueller microscope. Polynomial regression model was built using the maps of transmitted intensity, retardance, dichroism and depolarization to generate the predicted images. The statistical analysis of predicted images of gastric tissue sections with multi-curve fit suggests that Mueller microscopy combined with data regression and statistical analysis is an effective approach for quantitative assessment of the degree of inflammation in gastric tissue biopsies with a high potential in clinical applications.

Verified
Journal Article
Open access
PDF file
NGNabil Gastli
Nabil Gastli
MAMargaux Allain
Margaux Allain
DLDominique Lamarque
Dominique Lamarque
VAVered Abitbol
Vered Abitbol
ABAnnick Billoët
Annick Billoët
JRJosette Raymond
Josette Raymond
Reliable diagnostic methods are mandatory for effective management of Helicobacter pylori infection. Histology and culture are the most common invasive methods in current practice, even if molecular methods are gaining in importance. The performance of these conventional methods varies significantly. We conducted a retrospective study of 1540 adults and 504 children with gastric biopsies taken during endoscopy to assess the impact of bacterial load and the cagA virulence factor on the performance of H. pylori infection testing. The association between virulence and histology findings was also investigated. With 23S rRNA qPCR confirmed by glmM amplification as the gold standard, culture and histology had lower sensitivity, 74.4% and 73.3%, respectively. However, their sensitivity was enhanced (>90%) in biopsies with high bacterial load (qPCR Ct < 30). Positive cagA status of the strain was associated with high bacterial load (94.9%), thus resulting in more frequent positive culture (94.3%) and H. pylori histology detection (91.7%) and more severe lesions on histology (p < 0.001). Conversely, the cagA status of the strains was negative in 110/119 (92.4%) of biopsies with low bacterial load (qPCR Ct < 30), 82/90 (91.1%) with negative H. pylori histology detection and 119/131 (90%) with negative culture findings (p < 0.001). This study highlights the low sensitivity of conventional culture and histology that may lead to false negative diagnosis if used alone. H. pylori quantification associated with cagA genotyping in routine workflow are essential for a sensitive and reliable diagnosis, to identify patients at high risk and to manage eradication therapies.

1 October 1996 in European Journal of Pharmacology
Verified
Journal Article
Closed access
DLDominique Lamarque
Dominique Lamarque
BWBrendan J.R. Whittle
Brendan J.R. Whittle

30 April 2023 in Diagnostics
Verified
Journal Article
Open access
PDF file
MOMalgorzata Osmola
Malgorzata Osmola
CHCaroline Hemont
Caroline Hemont
NCNicolas Chapelle
Nicolas Chapelle
MVMarie-Anne Vibet
Marie-Anne Vibet
DTDavid Tougeron
David Tougeron
TMTamara Matysiak-Budnik
Tamara Matysiak-Budnik
Despite a global decrease, gastric cancer (GC) incidence appears to be increasing recently in young, particularly female, patients. The causal mechanism for this “new” type of GC is unknown, but a role for autoimmunity is suggested. A cascade of gastric precancerous lesions, beginning with chronic atrophic gastritis (CAG), precedes GC. To test the possible existence of autoimmunity in patients with CAG, we aimed to analyze the prevalence of several autoantibodies in patients with CAG as compared to control patients. Sera of 355 patients included in our previous prospective, multicenter study were tested for 19 autoantibodies (anti-nuclear antibodies, ANA, anti-parietal cell antibody, APCA, anti-intrinsic factor antibody, AIFA, and 16 myositis-associated antibodies). The results were compared between CAG patients (n = 154), including autoimmune gastritis patients (AIG, n = 45), non-autoimmune gastritis patients (NAIG, n = 109), and control patients (n = 201). ANA positivity was significantly higher in AIG than in NAIG or control patients (46.7%, 29%, and 27%, respectively, p = 0.04). Female gender was positively associated with ANA positivity (OR 0.51 (0.31–0.81), p = 0.005), while age and H. pylori infection status were not. Myositis-associated antibodies were found in 8.9% of AIG, 5.5% of NAIG, and 4.4% of control patients, without significant differences among the groups (p = 0.8). Higher APCA and AIFA positivity was confirmed in AIG, and was not associated with H. pylori infection, age, or gender in the multivariate analysis. ANA antibodies are significantly more prevalent in AIG than in control patients, but the clinical significance of this finding remains to be established. H. pylori infection does not affect autoantibody seropositivity (ANA, APCA, AIFA). The positivity of myositis-associated antibodies is not increased in patients with CAG as compared to control patients. Overall, our results do not support an overrepresentation of common autoantibodies in patients with CAG.

12 March 2022 in Diagnostics
Verified
Journal Article
Open access
PDF file
NCNicolas Chapelle
Nicolas Chapelle
MOMalgorzata Osmola
Malgorzata Osmola
JMJérôme Martin
Jérôme Martin
JBJustine Blin
Justine Blin
MLMaxime Leroy
Maxime Leroy
TMTamara Matysiak-Budnik
Tamara Matysiak-Budnik
Background: Analysis of serum biomarkers for the assessment of atrophic gastritis (AG), a gastric precancerous lesion, is of growing interest for identification of patients at increased risk of gastric cancer. The aim was to analyze the diagnostic performance of serum pepsinogen testing using another method, chemiluminescent enzyme immunoassay (CLEIA), as well as of other new potential biomarkers. Material and Methods: The sera of patients considered at increased risk of gastric cancer and undergoing upper endoscopy collected in our previous prospective, multicenter study were tested for pepsinogen I (PGI) and II (PGII), interleukin-6 (IL-6), human epididymal protein 4 (HE-4), adiponectin, ferritin and Krebs von den Lungen (KL-6) using the CLEIA. The diagnostic performance for the detection of AG was calculated by taking histology as the reference. Results: In total, 356 patients (162 men (46%); mean age 58.6 (±14.2) years), including 152 with AG, were included. For the detection of moderate to severe corpus AG, sensitivity and specificity of the pepsinogen I/II ratio were of 75.0% (95%CI 57.8–87.9) and 92.6% (88.2–95.8), respectively. For the detection of moderate to severe antrum AG, sensitivity of IL-6 was of 72.2% (95%CI 46.5–90.3). Combination of pepsinogen I/II ratio or HE-4 showed a sensitivity of 85.2% (95%CI 72.9–93.4) for the detection of moderate to severe AG at any location. Conclusion: This study shows that PG testing by CLEIA represents an accurate assay for the detection of corpus AG. Additionally, IL-6 and HE-4 may be of interest for the detection of antrum AG. Mini- Pepsinogens testing by chemiluminescent enzyme immunoassay is accurate for the detection of corpus atrophic gastritis. IL-6 and HE-4 maybe of interest for the detection of antrum atrophic gastritis.

29 August 2024 in Cancers
Verified
Journal Article
Open access
PDF file
TBThomas Bazin
Thomas Bazin
KNKarine Nozeret
Karine Nozeret
CJCatherine Julié
Catherine Julié
DLDominique Lamarque
Dominique Lamarque
ETEliette Touati
Eliette Touati
Gastric cancer (GC) is a major cause of cancer-related mortality worldwide. It is often associated with a bad prognosis because of its asymptomatic phenotype until advanced stages, highlighting the need for its prevention and early detection. GC development is preceded by the emergence of gastric preneoplasia lesions (GPNLs), namely atrophic gastritis (AG), intestinal metaplasia (IM), and dysplasia (DYS). GC is currently diagnosed by endoscopy, which is invasive and costly and has limited effectiveness for the detection of GPNLs. Therefore, the discovery of non-invasive biomarkers in liquid biopsies, such as blood samples, in order to identify the presence of gastric preneoplasia and/or cancer lesions at asymptomatic stages is of paramount interest. This comprehensive review provides an overview of recently identified plasma/serum proteins and their diagnostic performance for the prediction of GPNLs and early cancer lesions. Autoantibodies appear to be promising biomarkers for AG, IM and early gastric cancer detection, along with inflammation and immunity-related proteins and antibodies against H. pylori virulence factors. There is a lack of specific protein biomarkers with which to detect DYS. Despite the need for further investigation and validation, some emerging candidates could pave the way for the development of reliable, non-invasive diagnostic tests for the detection and prevention of GC.